Is Estrogen Useful in Low Libido or Arousal Problems?
Learning Objectives and CME/Disclosure Information
This activity is intended for healthcare providers delivering care to women and their families.
After completing this activity, the participant should be better able to:
1. Classify those symptoms which have been demonstrated to respond to estrogen and those which have not 2. Choose the use of estrogen for appropriate symptoms
Estimated time to complete activity: 0.25 hours
Susan J. Gross, MD, FRCSC, FACOG, FACMG President and CEO, The ObG Project
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Faculty: Susan J. Gross, MD, receives consulting fees from Cradle Genomics, and has financial interest in The ObG Project, Inc.
Planners and Managers: The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP have nothing to disclose.
Method of Participation and Request for Credit
Fees for participating and receiving CME credit for this activity are as posted on The ObG Project website. During the period from Dec 31 2017 through Dec 31 2021, participants must read the learning objectives and faculty disclosures and study the educational activity.
If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation. Upon registering and successfully completing the post-test with a score of 100% and the activity evaluation, your certificate will be made available immediately.
For Pharmacists: Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and The ObG Project. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.2 contact hours.
A patient complains of low libido or problems with arousal and is concerned that these might be a side effects of diminishing estrogen.
Assess the sexual concerns
If the sexual problems appear to be secondary to menopausal complaints associated with low levels of estrogen, consider prescribing estrogen
If sexual problems appear to be independent of other menopausal complaints, inform patient that there is currently limited evidence to suggest estrogen replacement helps with low libido or sexual arousal disorders
See ‘Related ObG Topics’ for other options to address low libido
Postmenopausal patients may be concerned that their lack of sexual desire is related to the lack of estrogen associated with menopause. Despite popular media suggesting otherwise, current research does not support the theory that prescribing estrogen for sexual concerns is recommended. However, in those cases where sexual concerns appear to be secondary to other issues of discomfort associated with menopause such as hot flushes, sleep disruption or vaginal atrophy, prescribing estrogen may be helpful.
Evidence to date to remains limited as to whether estrogen plays a significant role in female sexual functioning
A recent study demonstrated transdermal estrogen provides modest improvement in sexual function in healthy, recently menopausal women (Kronos Early Estrogen Prevention Study [KEEPS] published in JAMA Internal Medicine, 2017 – see ‘Related ObG Topics’ below)
A comprehensive history and physical is helpful to determine if the patient’s complaint is stemming from other menopausal symptoms where systemic estrogen may actually be appropriate, for example exhaustion and sleep disorders related to hot flashes or vaginal atrophy leading to pain on intercourse
Testosterone may be considered in those cases where the physician and patient are looking for direct medical intervention for low libido or arousal problems
Transdermal testosterone has been shown to be effective for the short-term treatment but minimal evidence exists for long-term use (longer than 6 months)
Testosterone for use in hypoactive sexual desire disorder in women is not currently FDA approved
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
NOT ENOUGH CME HOURS
It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan